title: With regard to the paper by Zannad et al. entitled Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment versus risk aversion.
authors.affiliation: Chief Scientific Advisor, Cardiac Safety Services, Quintiles, Durham, NC, USA rick.turner@quintiles.com.
authors.forename: J Rick
authors.initials: JR
authors.lastname: Turner
authors.affiliation: Research Team, Cardiac Safety Services, Quintiles, Mumbai, India.
authors.forename: Dilip R
authors.initials: DR
authors.lastname: Karnad
authors.affiliation: Core ECG Laboratory, Cardiac Safety Services, Global Head, Cardiac Safety Centre of Excellence, Quintiles, Mumbai, India.
authors.forename: Snehal
authors.initials: S
authors.lastname: Kothari
authors.affiliation: Therapeutic and Specialty Centers of Excellence, Quintiles, Durham, NC, USA.
authors.forename: Alan
authors.initials: A
authors.lastname: Metz
authors.affiliation: University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
authors.forename: Hitesh
authors.initials: H
authors.lastname: Patel
authors.affiliation: Diabetes Center of Excellence, Quintiles, Durham, NC, USA.
authors.forename: Erica
authors.initials: E
authors.lastname: Caveney
mesh_terms: D002318:Cardiovascular Diseases; D006801:Humans; D018570:Risk Assessment; D012307:Risk Factors